Generic Name and Formulations:
Dapsone 5%; gel.
Indications for ACZONE:
Wash skin and pat dry. Apply pea-sized amount to affected area in a thin layer twice daily in the AM & PM. Rub in gently and completely. Wash hands after use. Reevaluate if no improvement after 12 weeks.
Avoid in congenital or idiopathic methemoglobinemia. G6PD deficiency: may have increased risk of methemoglobinemia or hemolytic anemia; discontinue if occurs. Pregnancy. Nursing mothers.
Increased risk of hemolysis in G6PD-deficient patients with concomitant trimethoprim/sulfamethoxazole, other folic acid antagonists (eg, pyrimethamine), anticonvulsants, rifampin, St. John's wort. Increased risk of methemoglobinemia with concomitant sulfonamides, acetaminophen, chloroquine, nitrates, nitrites, nitrofurantoin, phenobarbital, phenytoin, primaquine, quinine, and others. Skin/hair discoloration with topical benzoyl peroxide.
Application site reactions (oiliness, peeling, dryness, erythema, pruritus).
Gel 5% (tubes)—30g, 60g, 90g; Gel 7.5% (pumps)—30g, 60g, 90g
Clinical Pain Advisor Articles
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness